Artivion (NYSE:AORT) Insider John Davis Sells 2,075 Shares of Stock

Artivion, Inc. (NYSE:AORT) insider John Davis sold 2,075 shares of the company’s stock in a transaction dated Tuesday, February 24th. The stock was sold at an average price of $35.69, for a total transaction of $74,056.75. Following the completion of the sale, the insider owned 188,868 shares in the company, valued at $6,740,698.92. This represents a 1.09% decrease in their position. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through this hyperlink.

Artivion Stock Up 3.8%

Shares of NYSE:AORT traded up $1.37 during mid-day trading on Thursday, hitting $37.15. 56,411 shares of the company traded hands, compared to its average volume of 390,480. The stock has a market cap of $1.78 billion, a P/E ratio of 185.77 and a beta of 1.59. The stock has a 50-day moving average price of $42.27 and a two-hundred day moving average price of $43.08. Artivion, Inc. has a 12-month low of $21.97 and a 12-month high of $48.25. The company has a current ratio of 3.53, a quick ratio of 2.62 and a debt-to-equity ratio of 0.49.

Artivion (NYSE:AORT) last released its quarterly earnings data on Thursday, February 12th. The company reported $0.17 EPS for the quarter, beating the consensus estimate of $0.14 by $0.03. The business had revenue of $118.30 million for the quarter, compared to the consensus estimate of $116.42 million. Artivion had a net margin of 2.21% and a return on equity of 7.43%. Artivion’s revenue for the quarter was up 19.2% on a year-over-year basis. On average, equities research analysts forecast that Artivion, Inc. will post 0.37 earnings per share for the current year.

Institutional Trading of Artivion

A number of large investors have recently made changes to their positions in the business. Squarepoint Ops LLC bought a new stake in shares of Artivion in the 2nd quarter valued at approximately $664,000. Kennedy Capital Management LLC lifted its stake in shares of Artivion by 20.8% during the second quarter. Kennedy Capital Management LLC now owns 367,762 shares of the company’s stock worth $11,437,000 after buying an additional 63,205 shares during the period. Oppenheimer Asset Management Inc. acquired a new stake in Artivion during the second quarter worth about $669,000. Sio Capital Management LLC increased its holdings in Artivion by 31.0% in the second quarter. Sio Capital Management LLC now owns 158,736 shares of the company’s stock valued at $4,937,000 after buying an additional 37,558 shares in the last quarter. Finally, Osterweis Capital Management Inc. acquired a new position in shares of Artivion in the second quarter worth about $3,750,000. 86.37% of the stock is currently owned by institutional investors.

Artivion News Summary

Here are the key news stories impacting Artivion this week:

• Positive Sentiment: Company beat recent quarterly estimates — revenue grew ~19% year‑over‑year and EPS topped consensus in the Feb. 12 report, supporting the bullish case for revenue momentum and margin recovery. Earnings & Company Page
• Positive Sentiment: Short interest fell materially in February (down ~15.4% month‑over‑month to ~1.39M shares, ~3.2% of float), lowering near‑term downside pressure from short covering and making upward moves easier to sustain. Short Interest/Insider Page
• Positive Sentiment: Large institutional moves show conviction: several funds (Summit Partners, Invesco, Goldman, Two Sigma) increased or initiated sizeable positions in recent quarters, suggesting longer‑term buy interest from professional investors. Institutional Holdings
• Neutral Sentiment: Analyst coverage is mixed but skewed positive: consensus is a “Moderate Buy” with a ~$49 average target, though several shops have trimmed price targets or moved to hold — signaling diverging views on near‑term upside. Analyst Notes
• Negative Sentiment: Substantial insider selling across senior management over Feb. 23–24 (CEO James P. Mackin sold multiple blocks totaling tens of thousands of shares, plus sales by the EVP, SVPs and CAO). While filings indicate open‑market sales (liquidity/rebalancing), the size and breadth of the dispositions can create short‑term selling pressure and investor unease. SEC filings: CEO Form 4 and related officer filings. CEO Form 4 EVP Form 4

Wall Street Analysts Forecast Growth

A number of equities analysts recently commented on AORT shares. Weiss Ratings upgraded Artivion from a “sell (d)” rating to a “hold (c-)” rating in a report on Friday, February 20th. Wall Street Zen cut shares of Artivion from a “buy” rating to a “hold” rating in a report on Saturday, February 14th. Oppenheimer reiterated an “outperform” rating and set a $50.00 target price on shares of Artivion in a research note on Friday, November 7th. Canaccord Genuity Group lowered their price objective on shares of Artivion from $51.00 to $48.00 and set a “buy” rating on the stock in a research report on Friday, February 13th. Finally, Needham & Company LLC reaffirmed a “buy” rating and set a $58.00 price target on shares of Artivion in a report on Monday, February 2nd. Six equities research analysts have rated the stock with a Buy rating and two have given a Hold rating to the company’s stock. Based on data from MarketBeat.com, the stock has a consensus rating of “Moderate Buy” and a consensus target price of $48.97.

Artivion Company Profile

Artivion, Inc (NYSE: AORT) is a global medical technology company that develops, manufactures and markets implantable tissue products and surgical devices for cardiac and vascular surgery. The company’s portfolio includes biologic implants derived from human and animal tissue, such as allografts and xenografts, as well as synthetic scaffolds and surgical adhesives. These products are designed to repair, reinforce or replace damaged cardiovascular and thoracic tissues during procedures such as aortic repair, heart valve surgery and vascular reconstruction.

Originally founded in 1984 under the name CryoLife, the company rebranded as Artivion in early 2022 to reflect its broader mission in cardiovascular innovation.